Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.

ABSTRACT:

Background

Chordoma is a rare but devastating tumor that arises in the cranial skull base or spine. There are currently no US Food and Drug Administration-approved targeted therapies for chordoma, and little understanding of whether using more than one therapy has benefit over monotherapy.

Objective

The objective of this study was to systematically review the current status of clinical trials completed for patients with chordoma to determine if multimodal therapy offers a benefit in progression-free survival over monomodal therapy.

Methods

We performed a systematic review of the literature according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines to review the available clinical trials of targeted therapy for chordoma. We comp

SUBMITTER: Akinduro OO 

PROVIDER: S-EPMC9286495 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature